叔丁基(单甲氧基)三甘醇 | 331992-12-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 叔丁基(单甲氧基)三甘醇
• 英文名称: tert-butyl 2,5,8,11-tetraoxatridecan-13-oate
• 英文别名: tert-butyl (monomethoxy)triethylene glycol acetate；tert-butyl(monomethoxy)triethylene glycol；CH3(CH2CH2O)3CH2COOt-Bu；Tert-butyl 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]acetate
• CAS: 331992-12-2
• 化学式: C₁₃H₂₆O₆
• 分子量: 278.346
• InChiKey: NMWYTLKVKWKSNC-UHFFFAOYSA-N

物化性质

• 沸点：
  332.9±27.0 °C(Predicted)
• 密度：
  1.022±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  叔丁基(单甲氧基)三甘醇 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 C₃₃H₄₅NO₈
  参考文献：
  名称：

  BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

  摘要：

  本文提供了一种苯并螺环烷衍生物，以及其制备方法和用途。具体而言，本文提供了一种式（I）化合物，或其药用可接受的盐、立体异构体或溶剂化合物，以及其制备方法，并用于制备治疗疼痛药物的用途。

  公开号：

  US20190161468A1
• 作为产物：
  描述：

  三甘醇单甲醚 、 溴乙酸叔丁酯 在 sodium hydride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 15.5h， 以50%的产率得到叔丁基(单甲氧基)三甘醇
  参考文献：
  名称：

  寡乙烯链对偶氮苯染料形成光响应纳米管的影响

  摘要：

  在甲基环己烷中研究了两亲性偶氮苯二元的自组装。二面体形成机械上易碎的纳米管。紫外线照射通过反式/顺式光异构化诱导纳米管解离成分子分散状态。可见光照射不会导致纳米管的重建，而由于光异构体的共聚集而获得了非晶膜。

  DOI：

  10.1002/ejoc.202000019

文献信息

• [EN] A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS<br/>[FR] CONJUGUÉ D'UN ANALOGUE DE TUBULYSINE AVEC DES LIEURS RAMIFIÉS
  申请人：HANGZHOU DAC BIOTECH CO LTD

  公开号：WO2019127607A1

  公开（公告）日：2019-07-04

  The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

  本发明涉及将一种管腔霉素类似物化合物与具有分支/侧链连接物的细胞结合分子结合，以实现结合物的更好传递和靶向治疗异常细胞。它还涉及一种将管腔霉素类似物分子与细胞结合配体结合的分支连接方法，以及在靶向治疗癌症、感染和自身免疫疾病中使用结合物的方法。
• 单分散聚乙二醇单甲醚修饰的丙泊酚前药的 制备与应用
  申请人：武汉大学

  公开号：CN108164419B

  公开（公告）日：2021-03-16

  本发明公开了一种结构新颖的单分散聚乙二醇单甲醚修饰的丙泊酚前药的制备与应用，属于有机化学与医药化工领域。单分散聚乙二醇单甲醚与丙泊酚通过可在体内降解的化学键相连分别制备出一系列碳酸酯型和乙酸酯型的丙泊酚前药。该方法通过调整单分散聚乙二醇单甲醚链的长度，可以合成出相应水溶性的丙泊酚前药，单分散聚乙二醇单甲醚链越长，水溶性就越好，水溶性的提高可以将其制备成水溶液的制剂，规避丙泊酚脂肪乳剂中脂肪乳的缺陷。本发明方法反应简单、条件温和、成本较低，便于工业化生产。
• Nucleolipid nanovectors as molecular carriers for potential applications in drug delivery
  作者：Luca Simeone、Gaetano Mangiapia、Carlo Irace、Antonio Di Pascale、Alfredo Colonna、Ornella Ortona、Lorenzo De Napoli、Daniela Montesarchio、Luigi Paduano

  DOI：10.1039/c1mb05143a

  日期：——

  Novel thymidine- or uridine-based nucleolipids, containing one hydrophilic oligo(ethylene glycol) chain and one or two oleic acid residues (called ToThy, HoThy and DoHu), have been synthesized with the aim to develop bio-compatible nanocarriers for drug delivery and/or produce pro-drugs. Microstructural characterization of their aggregates has been determined in pure water and in pseudo-physiological conditions through DLS and SANS experiments. In all cases stable vesicles, with mean hydrodynamic radii ranging between 120 nm and 250 nm have been revealed. Biological validation of the nucleolipidic nanocarriers was ensured by evaluation of their toxicological profiles, performed by administration of the nanoaggregates to a panel of different cell lines. ToThy exhibited a weak cytotoxicity and, at high concentration, some ability to interfere with cell viability and/or proliferation. In contrast, DoHu and HoThy exhibited no toxicological relevance, behaving similarly to POPC-based liposomes, widely used for systemic drug delivery. Taken together, these results show nucleolipid-based nanocarriers as finely tunable, multi-functional self-assembling materials of interest for the in vivotransport of biomolecules or drugs.

  我们合成了新型胸腺嘧啶或尿苷核脂，它们含有一条亲水性低聚（乙二醇）链和一个或两个油酸残基（称为 ToThy、HoThy 和 DoHu），目的是开发生物兼容的纳米载体，用于药物输送和/或生产原药。通过 DLS 和 SANS 实验，确定了它们的聚集体在纯水和假生理条件下的微观结构特征。在所有情况下都发现了稳定的囊泡，其平均流体力学半径介于 120 纳米和 250 纳米之间。核脂纳米载体的生物学验证是通过评估其毒理学特征来实现的。ToThy表现出微弱的细胞毒性，在高浓度时还会干扰细胞的活力和/或增殖。相比之下，DoHu 和 HoThy 则没有毒理学相关性，其表现与广泛用于全身给药的基于 POPC 的脂质体相似。综上所述，这些结果表明核脂质纳米载体是一种可微调的多功能自组装材料，可用于生物分子或药物的体内转运。
• Surfaces that resist the adsorption of biological species
  申请人：——

  公开号：US20020102405A1

  公开（公告）日：2002-08-01

  The present invention provides articles resistant to the adsorption of proteins, cells and bacteria. The articles can either have a chemical chain bonded thereon where the chemical chain can comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried such that an exposed surface of the article including the chemical chain is free of a hydrogen bond donor. The chemical chain, or plurality of chemical chains, can comprise a monolayer such as a self-assembled monolayer (SAM) which can be homogeneous (one type of SAM) or mixed, i.e. or more different types of SAMs. Other more specific examples of chemical chains are provided. The plurality of chemical chains can comprise a polymer such as a polyamine. In many aspects, the plurality of chemical chains is sufficiently free of cross-linking or branching. The present invention also provides an article capable of specific binding of a desired biomolecule while preventing non-specific binding of biomolecules.

  本发明提供了一种耐蛋白质、细胞和细菌吸附的物品。该物品可以在其上化学键合一种化学链，该化学链可以包括一个不含有氢键供体的末端基团，或者氢键供体被足够地埋藏，以使包括化学链的暴露表面不含有氢键供体。该化学链或多个化学链可以包括单分子层，例如自组装单分子层（SAM），可以是均质的（一种SAM）或混合的，即多种不同类型的SAM。提供了其他更具体的化学链的示例。多个化学链可以包括聚合物，例如聚胺。在许多方面，多个化学链足够不交联或分支。本发明还提供了一种能够特异性结合所需生物分子而防止非特异性结合生物分子的物品。
• Cholesterol-Based Nucleolipid-Ruthenium Complex Stabilized by Lipid Aggregates for Antineoplastic Therapy
  作者：Luca Simeone、Gaetano Mangiapia、Giuseppe Vitiello、Carlo Irace、Alfredo Colonna、Ornella Ortona、Daniela Montesarchio、Luigi Paduano

  DOI：10.1021/bc200565v

  日期：2012.4.18

  A novel ruthenium complex, linked to a cholesterol-containing nucleolipid (named ToThyCholRu), stabilized by lipid aggregates for antineoplastic therapy is presented. In order to retard the degradation kinetics typically observed for several ruthenium-based antineoplastic agents, ToThyCholRu is incorporated into a liposome bilayer formed by POPC. The resulting nanoaggregates contain up to 15% in moles of the ruthenium complex, and are shown to be stable for several weeks. The liposomes host the ruthenium nucleolipid complex with the metal ion surrounded by POPC lipid headgroups and the steroid moiety inserted in the more external acyl chain region. These ruthenium-containing liposomes are more effective in inhibiting the growth of cancer cells than a model NAMI-A-like ruthenium complex, prepared for a direct evaluation of their anti-proliferative activity. These results introduce new perspectives in the design of innovative transition-metal-based supra-molecular systems for anticancer drug vectorization.